Ronald Levy
Impact in
- Immunology top 0.01%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Genetics top 0.02%
- Chronic Lymphocytic Leukemia Research
Papers in
- Immunology 239
- Immunotherapy and Immune Responses 132
- Immune Cell Function and Interaction 77
- T-cell and B-cell Immunology 58
-
- Monoclonal and Polyclonal Antibodies Research 224
- Co-authors
- Debra K. Czerwinski (93 shared papers)Wen‐Kai Weng (17 shared papers)Izidore S. Lossos (48 shared papers)Shoshana Levy (46 shared papers)Roger A. Warnke (28 shared papers)L A Lampson (4 shared papers)Ash A. Alizadeh (40 shared papers)David G. Maloney (11 shared papers)
- Journals
- Blood (151 papers)The Journal of Immunology (47 papers)Journal of Clinical Oncology (30 papers)Proceedings of the National Academy of Sciences (24 papers)The Journal of Experimental Medicine (14 papers)
- Partner nations
- United StatesFranceIsrael
In The Last Decade
Ronald Levy
572 papers receiving 39.7k citations
Ronald Levy's Hit Papers
Peers
Comparison fields: 5 of 180
- Immunology 19.1k
- Genetics 7.3k
- Pathology and Forensic Medicine 11.6k
- Radiology, Nuclear Medicine and Imaging 10.9k
- Oncology 12.8k
Countries citing papers authored by Ronald Levy
This map shows the geographic impact of Ronald Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Levy more than expected).
Fields of papers citing papers by Ronald Levy
This network shows the impact of papers produced by Ronald Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Levy. The network helps show where Ronald Levy may publish in the future.
Co-authors
The 25 scholars most cited alongside Ronald Levy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 588 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Hit paper breakdown → | 1998 | 2158 |
| 2 | Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells Hit paper breakdown → | 1996 | 1516 |
| 3 | IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Hit paper breakdown → | 1997 | 1356 |
| 4 | Two populations of Ia-like molecules on a human B cell line. Hit paper breakdown → | 1980 | 1030 |
| 5 | Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma Hit paper breakdown → | 2003 | 993 |
| 6 | Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma Hit paper breakdown → | 2010 | 858 |
| 7 | Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody Hit paper breakdown → | 1982 | 716 |
| 8 | Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes Hit paper breakdown → | 2004 | 710 |
| 9 | Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Hit paper breakdown → | 1994 | 605 |
| 10 | Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Hit paper breakdown → | 2009 | 590 |
| 11 | IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Hit paper breakdown → | 1997 | 529 |
| 12 | Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment Hit paper breakdown → | 2000 | 526 |
| 13 | 1992 | 440 | |
| 14 | 2002 | 424 | |
| 15 | 1999 | 408 | |
| 16 | 2010 | 400 | |
| 17 | 2000 | 382 | |
| 18 | 1997 | 368 | |
| 19 | 1985 | 357 | |
| 20 | Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK Hit paper breakdown → | 2015 | 355 |
About Ronald Levy
Ronald Levy is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine, Oncology and Molecular Biology, having authored 588 papers that have together received 41.7k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (224 papers), Lymphoma Diagnosis and Treatment (190 papers), Immunotherapy and Immune Responses (132 papers), CAR-T cell therapy research (113 papers), Chronic Lymphocytic Leukemia Research (90 papers), Immune Cell Function and Interaction (77 papers), Glycosylation and Glycoproteins Research (66 papers) and T-cell and B-cell Immunology (58 papers). The work is most often cited by research in Immunology (19.1k citations), Genetics (7.3k citations), Pathology and Forensic Medicine (11.6k citations), Radiology, Nuclear Medicine and Imaging (10.9k citations) and Oncology (12.8k citations). Ronald Levy has collaborated with scholars based in United States, France and Israel. Frequent co-authors include Debra K. Czerwinski, Wen‐Kai Weng, Izidore S. Lossos, Shoshana Levy, Roger A. Warnke, L A Lampson, Ash A. Alizadeh, David G. Maloney, DG Maloney and John M. Timmerman. Their work appears in journals such as Blood, The Journal of Immunology, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.